Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

3yrs ago Private Equity privateequitywire Views: 474

IK portfolio company Klingel medical metal acquires puracon from SHS

Submitted 02/12/2020 - 4:46pm

SHS Gesellschaft für Beteiligungsmanagement mbH (SHS), based in Tübingen, is selling its shares in puracon to Klingel medical metal, a portfolio company of IK Investment Partners. 

With 600 employees, Klingel Group is one of the leading companies in the field of precision machining of high-strength materials such as stainless steel and titanium for the production of medical technology products made of metal. The purchase of puracon allows Klingel to benefit from valuable synergies as contract developer, manufacturer and packer and offer its worldwide medical technology customers a complete range of services based on the “one-stop-shop” principle. This is already the third acquisition for Klingel since IK Investment Partners acquired a stake in 2018.

SHS has been active as an investor in the field of medical technology and life sciences for more than two decades. This makes SHS one of the most experienced investment companies in this sector currently investing from SHS fund V.

At the end of 2015, SHS took a stake in puracon GmbH based in Rosenheim. As a full-service partner for the medtech industry, puracon offers efficient packaging and validation solutions for medical technology products: primarily implants and instruments. Thus, puracon is part of the validated process chain of implants and the final station before the sterile product is used for patients in the hospital.

Sascha Alilovic, Managing Partner of SHS, says: “With Klingel medical metal, puracon is able to continue to pursue a targeted course of growth. Klingel thinks about the long-term. The company has been in the market since 1986 and is today one of the leading suppliers in its field. Our goal was to support puracon on the road to profitable growth. We've achieved this, and now it's time to ignite the next stage – and Klingel is the perfect partner for this.”

Ralf Petrawitz, Managing Partner and CEO of Klingel, plans to significantly expand the group’s offering for medical technology customers worldwide on the basis of this acquisition. “puracon is a very good addition to an already extensive product range for our demanding customers from the medical technology sector. As a result, we are now able to offer services in the field of validation and packaging within the Klingel Group. These factors enable us to specifically strengthen our competitive position and make us fit for the future.”

Ruth Gessner, Managing Director of puracon, says: “Together with SHS, we as a puracon team have been able to significantly expand our customer base over the last five years, thereby generating strong growth. With Klingel Group, we will take the next step and achieve synergies that will benefit both our customers and our employees. We look forward to working with them.”

Tags Deals & Transactions Acquisitions

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.